Novo-Nordisk A/S NVO
i
Market datapartial · fetched 2026-11-08T00:51:37.155Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:58:27.843243028Z
FundamentalsAlpha Vantage · unavailable
Novo-Nordisk A/S options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 42.05 | 36.6% | 4.7% | 38.80 | 37.4% | 4.4% |
| 25Δ | 41.74 | 37.1% | 4.2% | 39.13 | 37.2% | 3.7% |
| 30Δ | 41.45 | 37.4% | 3.6% | 39.40 | 37.9% | 3.3% |
| 35Δ | 41.18 | 37.3% | 3.2% | 39.66 | 37.8% | 2.9% |
| 40Δ | 40.91 | 37.3% | 2.7% | 39.93 | 37.2% | 2.4% |
| 45Δ | 40.66 | 37.5% | 2.4% | 40.17 | 37.2% | 2.1% |
| 50Δ | 40.42 | 37.5% | 2.1% | 40.42 | 37.3% | 1.8% |
| 55Δ | 40.18 | 37.1% | 1.7% | 40.66 | 37.2% | 1.5% |
| 60Δ | 39.93 | 37.0% | 1.5% | 40.90 | 36.9% | 1.3% |
| 65Δ | 39.66 | 37.7% | 1.2% | 41.26 | 40.6% | 1.1% |
| 70Δ | 39.41 | 37.6% | 1.0% | |||
| 75Δ | 39.18 | 35.9% | 0.8% | 42.51 | 56.9% | 1.0% |
| 80Δ | 38.89 | 35.3% | 0.6% | |||
20Δ
- Pseudo strike
- 42.05
- IV
- 36.6%
- B/E move
- 4.7%
- Pseudo strike
- 38.80
- IV
- 37.4%
- B/E move
- 4.4%
25Δ
- Pseudo strike
- 41.74
- IV
- 37.1%
- B/E move
- 4.2%
- Pseudo strike
- 39.13
- IV
- 37.2%
- B/E move
- 3.7%
30Δ
- Pseudo strike
- 41.45
- IV
- 37.4%
- B/E move
- 3.6%
- Pseudo strike
- 39.40
- IV
- 37.9%
- B/E move
- 3.3%
35Δ
- Pseudo strike
- 41.18
- IV
- 37.3%
- B/E move
- 3.2%
- Pseudo strike
- 39.66
- IV
- 37.8%
- B/E move
- 2.9%
40Δ
- Pseudo strike
- 40.91
- IV
- 37.3%
- B/E move
- 2.7%
- Pseudo strike
- 39.93
- IV
- 37.2%
- B/E move
- 2.4%
45Δ
- Pseudo strike
- 40.66
- IV
- 37.5%
- B/E move
- 2.4%
- Pseudo strike
- 40.17
- IV
- 37.2%
- B/E move
- 2.1%
50Δ
- Pseudo strike
- 40.42
- IV
- 37.5%
- B/E move
- 2.1%
- Pseudo strike
- 40.42
- IV
- 37.3%
- B/E move
- 1.8%
55Δ
- Pseudo strike
- 40.18
- IV
- 37.1%
- B/E move
- 1.7%
- Pseudo strike
- 40.66
- IV
- 37.2%
- B/E move
- 1.5%
60Δ
- Pseudo strike
- 39.93
- IV
- 37.0%
- B/E move
- 1.5%
- Pseudo strike
- 40.90
- IV
- 36.9%
- B/E move
- 1.3%
65Δ
- Pseudo strike
- 39.66
- IV
- 37.7%
- B/E move
- 1.2%
- Pseudo strike
- 41.26
- IV
- 40.6%
- B/E move
- 1.1%
70Δ
- Pseudo strike
- 39.41
- IV
- 37.6%
- B/E move
- 1.0%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 39.18
- IV
- 35.9%
- B/E move
- 0.8%
- Pseudo strike
- 42.51
- IV
- 56.9%
- B/E move
- 1.0%
80Δ
- Pseudo strike
- 38.89
- IV
- 35.3%
- B/E move
- 0.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 34.20% | |
| 33.20% | |
| 31.16% | |
| 32.36% | |
| 29.54% | |
| 31.15% | |
| 30.37% | |
| 32.82% | |
| 33.52% | |
| 30.29% | |
| 32.33% | |
| 42.44% | |
| 32.68% | |
| 32.21% | |
| 29.44% | |
| 30.54% | |
| 31.53% | |
| 33.63% | |
| 31.95% | |
| 32.21% | |
| 36.05% | |
| 34.88% | |
| 33.22% | |
| 34.72% | |
| 34.86% | |
| 36.10% | |
| 37.88% | |
| 37.92% | |
| 38.29% | |
| 36.32% | |
| 32.83% | |
| 31.20% | |
| 30.44% | |
| 28.35% | |
| 31.14% | |
| 30.91% | |
| 30.99% | |
| 36.63% | |
| 27.42% | |
| 31.02% | |
| 29.00% | |
| 31.97% | |
| 32.07% | |
| 32.70% | |
| 34.41% | |
| 34.96% | |
| 35.45% | |
| 34.15% | |
| 37.13% | |
| 36.38% | |
| 41.57% | |
| 38.72% | |
| 38.83% | |
| 41.57% | |
| 43.21% | |
| 43.71% | |
| 44.88% | |
| 48.49% | |
| 52.78% |
Drug Manufacturers - General
NVS
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
More →OGN
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine,…
More →PFE
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company…
More →SNY
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The…
More →ABBV
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
More →AMGN
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular…
More →